Format

Send to

Choose Destination
J Glaucoma. 2007 Aug;16(5):437-9.

Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma.

Author information

1
Ophthalmic Research Center and Department of Ophthalmology, Labbafinejad Medical Center, Shaheed Beheshti Medical University, Tehran, Iran. shahinyazdani@yahoo.com

Abstract

Neovascular glaucoma is a secondary glaucoma with grave prognosis which follows ischemic retinal disorders in the majority of cases. Mediators that induce new vessel formation such as the vascular endothelial growth factor-A seem to play a key role in the pathophysiology of this condition. Herein, we report 2 cases with neovascular glaucoma secondary to ischemic central retinal vein occlusion who received treatment with intravitreal bevacizumab (Avastin) a nonselective antibody against vascular endothelial growth factor-A. Both patients demonstrated dramatic short-term response in terms of intraocular pressure reduction and regression of neovascularization.

PMID:
17700285
DOI:
10.1097/IJG.0b013e3180457c47
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center